January 25, 2013
Renewing the Project BioShield Act: What Has It Bought and Wrought?
In the next several months, the president and members of Congress will decide whether to continue the funding and authorities associated with Project BioShield, which seeks to expand the U.S. stockpile of medical countermeasures for potential chemical, biological, radiological and nuclear attacks. In Renewing the Project BioShield Act: What Has It Bought and Wrought?, Dr. Robert Kadlec, a consultant with RPK Consulting, writes that Project BioShield has achieved its strategic objectives and merits continued support and funding. He argues that the president and Congress should affirm its value as a critical insurance policy against the risk of these types of attacks.
More from CNAS
-
Russia's Evolving Nuclear Doctrine and its Implications
In this report, Robert M. Gates Senior Fellow Elbridge Colby provides a baseline of Russian thinking on how Moscow looks at these options....
By Elbridge Colby
-
Is North Korea a Nuclear State?
If the global norm against nuclear proliferation is to retain meaning, North Korea must remain isolated from the international community in certain respects. But that doesn’t...
By Van Jackson
-
The Partnership: Five Cold Warriors and Their Quest to Ban the Bomb (Part III)
On Wednesday, January 4, 2012 from 6:00 to 8:30 p.m., the Center for a New American Security (CNAS) held a book launch for The Partnership: Five Cold Warriors and Their Quest ...
-
The Partnership: Five Cold Warriors and Their Quest to Ban the Bomb (Part II)
On Wednesday, January 4, 2012 from 6:00 to 8:30 p.m., the Center for a New American Security (CNAS) held a book launch for The Partnership: Five Cold Warriors and Their Quest ...